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7. Translational research:
entrepreneurship, advocacy and
programmatic work in the
governance of biomedical innovation
Etienne Vignola-Gagné, Peter Biegelbauer
and Daniel Lehner
7.1 INTRODUCTION
A number of conceptual and disciplinary splits reduce the analytical
power of STI policy and systems analyses. Most notably, STI policy
analyses have tended to frame these processes as out of their boundaries,
despite the recognition that debate or bargaining as processes shape
policy instruments and their targets in a world of constrained resources
(Holzinger, 2004; Saretzki, 2009), making the formulation and
implementation of policy instruments an inherently political matter
(Meadowcroft, 2009; Biegelbauer and Hansen, 2011; Geels and Verhees,
2011). Yet, several decades of policy analysis provide ample proof that
only in the rarest of cases do policy interventions come out of the blue.
Normally they are the result of struggles for power, the ambition to be
represented, to have one’s interests included, to learn from experience, to
win an argument, to see a set of ideas vested with the power to explain,
and the like (for example Truman, 1956; Lasswell, 1970; Hall, 1993;
Sabatier and Jenkins-Smith, 1993; Gottweis, 1998; Parsons, 2003).
Therefore power struggles are not the only highly political element in
policy-making. Bargaining, entrepreneurship and advocacy may be
required even for the continued maintenance and performance of innov-
ation systems. Complementarities need to be activated and reactivated.
Interdependencies between areas of expertise and between organizations
often ‘fall out’ and become dysfunctional. Here, we will show that
governance is not only about the creation of legitimacy towards a broad
public for the ‘reception of technology’, but also the building of
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legitimacy within a network to build support for the ‘reception’ of an
organizational form. Indeed, governance does not end at the doorstep of
an organization; rather, the term has an inside and an outside quality. We
are interested in both, the governance of change on the level of policies,
and on the level of organizations, their structures, norms and values (Hall
and Taylor, 1996; Peters, 1999; Hollingsworth, 2000).
Initiative, entrepreneurship and advocacy are constantly required at the
organizational level to ensure collaboration and coordination. In these
contexts of high ambivalence, entrepreneurial activity is also required to
negotiate which policy instruments will be marshalled in the specific
context, and how. An important condition to achieve successful advocacy
by entrepreneurs are sets of policy rationales and/or programmatic
statements that clarify targets and tactics for collective action. STI
policies in implementation are confronted with a policy field in which
varying sets of skilled actors are making them part of their opportunity
structures when they try, for example, to raise funds for new projects or
institutions. This is the case for ‘hard’, that is, regulatory and distributive,
and ‘soft’, that is, information delivery and community formation meas-
ures, both of which are subject to interpretation by various actors. In the
process, new rationales, scientific concepts and programmatic frame-
works are utilized as framings: opportunistically, in order to gain
funding; as sense-making tools, in order to interpret social problems and
environments; but also instrumentally, as mechanisms to coordinate and
channel the efforts of the range of actors brought together by advocacy
efforts.
In short, Chapter 7 focuses on change in some of the experimental and
organizational practices that are central components of socio-technical
systems. It uses novel observations drawn from case studies of bio-
medical innovation systems reform to trace the role of selected param-
eters in this process of transforming existing practices. Specifically, we
look at the role of (1) programmatic statements; (2) their advocacy by
entrepreneurs and (3) their interplay with existing and new policy
instruments, in explaining the governance of socio-technical change. This
analytical strategy could have explanatory power in other cases of
socio-technical change where policy design and implementation define
parameters of the process.
The three case studies each revolve around efforts in the implementa-
tion of translational research (TR) programmes in biomedical RTD sites
located in Austria and Germany. TR can be defined as a policy rationale
(Braun, 2005) that first problematizes current practices in biomedical
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practices, offering a distinct diagnostic of well-discussed ‘crisis situ-
ations’ in biomedical innovation systems. These innovation crises
include:
(1) public disappointment with the outcomes for patients of big science
projects such as the Human Genome Project;
(2) a perceived widening gap between the practice of academic medi-
cine and the advances of molecular biology and
(3) decreased RTD productivity in the pharmaceutical industry which
has led to the loss of thousands of RTD jobs (Kraft, 2013;
Vignola-Gagné, 2014).
Second, TR advocates championing a specific set of scientific
approaches, organizational arrangements and policy packages as the way
out of these problems. The most prominent interventions on biomedical
innovation systems and attendant policies that are advocated through TR
include:
+ Closer integration of clinical experience with cutting-edge labora-
tory experimentation (including sequencing technologies and bio-
marker discovery experiments), notably through forms of ‘patient-
oriented research’ and the development of experimental routines
within clinical trials.
+ Investment of research monies and scientific work capacity in ‘gap
areas’, such as clinical pharmacology and drug development as a
scientific/engineering problem.
+ Redistributed and new professional roles across the continuum of
labour in biomedical innovation, including greater leadership from
clinician-scientists.
+ Greater coordination and orientation of innovation projects, to
increase efficiency and reduce trial-and-error in intervention devel-
opment.
As the dimensions above make clear, much of the TR rationale is aimed
explicitly at change in the governance of biomedical innovation systems
rather than techno–scientific change alone. Nevertheless, the TR rationale
is entangled with broad developments brought on by genomic sequencing
technologies, continuing reform of clinical research, past achievements
and desired futures. Prior to the establishment of the initiatives studied in
Chapter 7, TR had been used since the 1990s, in the US most notably, to
justify and orient policy-driven efforts targeting the dimensions men-
tioned above. The TR rationale attempts to harness and orient change in
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biomedical innovation systems brought on by advances in genomics
towards a specific set of outcomes, both techno-scientific and govern-
mental.
The three cases of implementation of TR rationales into regional STI
policies that will be studied below highlight the importance of the
interplay between scientific entrepreneurs and explicit programmes of
change in reforming experimental and organizational practices in bio-
medical innovation. Entrepreneurs and advocates of TR negotiate the
formulation and implementation of pre-existing policy instruments to
build their networks, draw on higher-level debates about the legitimacy of
biomedical innovation to frame their action and shape the role of other
actors. These findings are relevant for the pillars of theory building
introduced by Borrás and Edler (2014), highlighting how advocacy,
entrepreneurship and governance processes around the design and
implementation of policy instruments (pillar 2) are themselves entangled
with structures of opportunity (pillar 1) and in processes of legitimacy
building (pillar 3).
Detailing our understanding of how: (1) policy rationales and pro-
grammes of socio-technical change; (2) advocacy works to enrol allies
for these programmes and (3) entrepreneurs interact to produce change in
experimental and organizational practices through TR initiatives studied
here, raises the following research questions:
+ How is a global rationale such as TR made use of in locales far
removed from its origins in Austria and Germany?
+ How are programmatic statements, concepts and assumptions about
current crises and benefits of the TR-model used to shape or drive
socio-technical change, and to shape or drive change in related
governance arrangements?
+ How do entrepreneurs engage in advocacy activities and deploy
programmatic statements in their innovation practices, and how do
these interact with policy instruments already deployed in the field?
The rest of Chapter 7 will be structured as follows: Section 7.2 reviews
previous efforts to use policy rationales, programmatic statements and the
role of entrepreneurs as analytical units in order to explain change in
socio-technical systems and their governance. Section 7.2 highlights
especially the potential contribution of the two categories ‘entrepreneur’
and ‘advocacy work’ to this research agenda. Section 7.3 provides a brief
overview of our data collection and analytical strategies. Section 7.4
presents and analyses our empirical material, starting with a review of the
emergence and evolution of TR rationales in the USA, and later
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internationally (section 7.4.1). This step is essential for understanding the
interventions advocated by the entrepreneurs in our case studies. Sub-
section 7.4.2 details case study material, with observations structured
along the three pillars by Edler and Borrás (2014). The presentation of
the policy instruments deployed in each initiative is successively context-
ualized with a view to the entrepreneurial (section 7.4.2.3 – pillar
opportunity structures and capable agents) and advocacy work (section
7.4.2.4 – pillar legitimacy) that has aligned and framed them. Section 7.5
concludes with a discussion of the findings, detailing the crucial role of
entrepreneurs and their advocacy of TR programmes in producing change
in socio-technical systems and their governance mechanisms.
7.2 LITERATURE REVIEW: RATIONALES,
PROGRAMMATIC STATEMENTS AND
ENTREPRENEURS
To understand the role of policy rationales and programmes in managing
change in socio-technical systems, one can follow along the lines of work
that aims to combine traditions of analysis in the economics of innov-
ation and in the politics of policy (to use the terms of Jacobsson and
Lauber, 2006). One approach employed in this strand of works has been
to identify ‘technology-specific coalitions’ that ‘engage in wider political
debates in order to gain influence over institutions and secure institu-
tional alignment’ (Jacobsson and Lauber, 2006, p. 259). While Geels and
Verhees (2011) have also studied the role of coalitions, cognitive frames
and discourses in innovation systems and policy, they have yet to look in
detail at how these processes reorganize systems of knowledge produc-
tion, for example at the level of mundane experimental and institutional
practice. Hillman et al. (2011) have provided STI policy and systems
analysts with typologies of parameters for modelling the steering action
of governance arrangements on innovation systems. Governance in
innovation systems may include regulatory, market, cognitive and norma-
tive mechanisms. These authors rightly point out the unique role of
public or governmental policy-makers in shaping and performing the
governance of innovation systems. Nevertheless, the current chapter
should make it clearer that while governmental actors may be obligatory
passage points in governance processes, they are not the critical source of
agency for change.
Elsewhere, scholars have combined the analysis of ‘traditional STI’
policy instruments and of ‘modes/strategies of governance’ by deploying
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a more dynamic approach to system building and resource utilization.
They have looked at the formation of networks to establish shared
resources, including reputational capital, standardization authorities or
financial resources (Musiolik et al., 2012). An important finding has been
that the system building process is partly determined by the type of
networks that lead these efforts and the resources they have access to.
This opens a path to further analyses of how policy instruments are
actively elaborated and operationalized within the mundane practices of
innovation, notably by highly entrepreneurial local actors.
Entrepreneurs have been the subject of a long-standing line of work in
economics. These studies have emphasized the role of individuals in
organizing or catalysing institutional change, taking risks and building
alliances for achieving their aims (Bergeron et al., 2013). The concept
has now been integrated across the social sciences, and the policy
entrepreneur or change entrepreneur has emerged as a useful analytical
unit to understand policy change. Interesting findings from the attendant
literature have highlighted how entrepreneurs realize their interests by
transforming the social space and institutional arrangements they evolve
in, rather than reproducing them; how they create and frame collective
crises and direct attention towards specific resources to solve them; and
how they play on the fragmentation of social systems and boundaries or
differences between groups and institutions to generate innovation and/or
benefit (Bergeron et al., 2013; Castel and Friedberg, 2010).
Authors have also highlighted the interaction between entrepreneurs
and policy rationales or programmes in pushing governance change.
Hassenteufel et al emphasize the determination of ‘programmatic actors’
on the content of policy change, on the legitimization of some program-
matic statements and the marginalizing of others. ‘By selecting, translat-
ing, recombining, and, most important, imposing ideas, they fulfil a
genuinely creative and constructive role’ (Hassenteufel et al., 2008,
p. 529). Programmatic statements are an essential component of policy
change, since crises and external destabilizations on policy processes do
not alone determine solutions.
These findings are in line with the original formulation of the
advocacy-coalition framework (ACF), formulated by Paul Sabatier and
Hank Jenkins-Smith, who state that policy change is mainly induced by
external effects such as economic crises or natural disasters, rather than
by policy entrepreneurs. Indeed, the ACF has been less interested in the
role of entrepreneurs, but more focused on the level of a policy
subsystem and the advocacy coalitions, which are seen as the main
constituent of policy fields. In the ACF, policy advocates are the prime
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movers of advocacy coalitions, being linked by shared policy beliefs and
interests (Sabatier and Jenkins-Smith, 1993; Sabatier, 1998).
Hassenteufel and colleagues oppose programmatic actors compared to
policy entrepreneurs in that the latter are seen mostly as brokers and
packagers but not creators. Such a strict delineation between the two
categories is questionable, however. Indeed, transfer and brokering rarely
leaves policy content intact. Clavier (2010) has shown the importance of
the self-initiative of local entrepreneurs in diffusing and implementing
public health and health care policies elaborated by the World Health
Organization. Much like TR rationales and other scientific programmes,
WHO policies are proposed interventions that are not intrinsically backed
with financial or regulatory obligation. Their careers rest on persuasion,
marketing and advocacy. Clavier’s examples provide a clear view of the
crucial role played by the combination of broadly circulated programmes
and policy rationale, as well as appropriation by local entrepreneurs for
enacting local change of practices and institutional arrangements.
Similarly, Peter Biegelbauer finds that in Austrian RTD policy-making,
major programmes usually are the result of policy entrepreneurs’ actions
with entrepreneurs in most cases (also) playing an important part in the
creation and (re)combination of policy ideas (2007, 2013b).
In the science, technology and society (STS) literature, forms of
advocacy have been captured in actor-network theory analyses of the
construction of innovation networks. Especially, a recent iteration of the
theory has drawn attention to the future-oriented work that is performed
to justify and, indeed, advocate for certain technological options rather
than others (van Lente and Rip, 1998; Hedgecoe and Martin, 2003).
Advocacy through raising technological expectations is here considered a
crucial strategy for building new networks of actors and artefacts, and
thus conducting socio-technical change. Arguments and rationales about
preferred courses for collective action have also been shown to be an
important component of the implementation and effectiveness of policy
formulated by governmental agencies (Borrás and Radaelli, 2011).
7.3 RESEARCH STRATEGY
A critical mass of attention has recently been afforded to TR rationales
within the biomedical innovation community, with a number of initiatives
being put into place internationally (Shahzad et al., 2011; von Roth et al.,
2011). Here, we mobilize case studies of TR-related entrepreneurship in
three initiatives established in Austria and Germany. The selected initia-
tives have been launched in the last ten years and have been explicitly
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construed by their promoters as being focused on TR. The initiatives
offer a degree of diversity and contrasting experiences to allow for
in-depth comparison. Taken as an ensemble, the initiatives should consti-
tute a broadly typical panel of cases. In a first case study (TRAIN), a
core group of entrepreneurs very actively advocate for the TR model to
reform regional innovation practices. Based on their work, new mechan-
isms of coordination, for what were previously dispersed and discrete
experimental projects, are being put into place and renewed legitimacy is
offered to RTD activities. In a second case study (ASC), technological
change is emphasized, with the other dimensions only marginally pres-
ent. The absence of a core single or group of entrepreneurs is noticeable
here, and both advocacy activities and uptake of the rationale appear to
be low. Use of TR was of a highly instrumental character. The third
initiative (OncoTyrol) offers a middle case in that it is characterized by a
strong group of entrepreneurs, but with less pronounced advocacy work.
Financial resources are used as driver of change, more so than program-
matic statements, although change is aimed in part at the implementation
of the TR model presented above. TR rationales thus have more of a
guiding role, but are also crucial to legitimize the strongly centralized
and top-down mode of coordination encountered in this consortium.
For each case study, semi-directed interviews were conducted with
coordinators, administrators, research leaders and policy-makers, who
had been identified as playing a central role in the establishment and
maintenance of the respective initiative (six interviews for the TRAIN
case study; seven for the OncoTyrol case study; 11 for the Anna-Spiegel-
Center case study). Interviews and relevant documents were coded and
analysed following an analytical grid that aimed to capture the diachronic
development of the initiatives, who was involved and how, the relations
to the international policy discussion, coordination issues, governmental
support and the features of the experimental practices deployed locally.
Lastly, this discrete investigation into TR initiatives was part of a
broader research programme concerned with understanding the origins
and implications of TR as a ‘reform movement’ in contemporary bio-
medical innovation. Even if they do not form the focus of analysis here,
our reflections on this topic have also drawn from 39 further interviews
conducted in Germany, EU-networks and the USA, as well as a docu-
ment analysis of governmental white papers and approximately 200
editorials, commentaries and reviews about TR, that are published in
peer- reviewed biomedical journals.
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7.4 RESULTS
TR is a policy rationale that appeared in the early 1990s. More
specifically, it advocates for certain institutional and experimental
reforms as privileged means to solve a number of crises that have shaken
biomedical innovation systems since the 1970s (Vignola-Gagné and
Biegelbauer, 2013).
7.4.1 Translational Research: Scope and Novelty
Section 7.4.1 looks at these constitutive crises and the kind of structural
changes in biomedical innovation that TR advocates aim for.
In the 1970s, the character of biomedical research was irrevocably
changed by the steady expansion of molecular biology approaches in the
field. Whereas the period immediately after World War 2 until the 1960s
saw a ‘golden-age’ of research performed by medical doctors in close
proximity to clinical contexts and practices, a paradigm retrospectively
dubbed ‘patient-oriented research’ (Swazey and Fox, 2004), the new
approach emphasized the control and replicability of laboratory systems
and modelling. Molecular biologists were slowly filling an increasing
number of research positions at academic medical centres and university
clinics, and also started to systematically outperform medical doctors in
obtaining National Institutes of Health research funding. Starting in the
late 1970s, but lasting up to now, a number of biomedical policy actors
and academic medicine leaders started to problematize the situation of
these clinician-scientists (for primary literature see: Wyngaarden, 1979;
Nathan, 2002; for secondary analysis see: Wilson-Kovacs and Hauskeller,
2012; Vignola-Gagné, 2014). They argued that these professionals pos-
sessed a unique dual expertise in both clinical care and clinical or
laboratory research, and were thus privileged drivers of biomedical
innovation with relevance to patients. Yet, the increasing sophistication of
molecular biology made them experience an increasing ‘gap’ between
both areas of practice, and increased public support was necessary to
enable these clinician-scientists to be competitive again in funding calls.
In 1991, with the establishment of a number of specialized centres for
clinical oncology research by the National Cancer Institute in the USA,
the notion of TR was first introduced and was immediately associated
with ongoing policy discussions about the future of clinician-scientists
(Cancer Letter, 1991). Major TR initiatives that came later also planned
support for clinician-scientists (for primary literature see: Zerhouni,
2005; Borstein and Licinio, 2011; for secondary analysis see: Vignola-
Gagné, 2014).
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The perception of a gap or disconnection between molecular biology-
driven biomedical research and clinical application gained much broader
currency in the early 2000s, in the immediate aftermath of the inter-
national Human Genome Project. This big science project of unpre-
cedented scope in biology and medicine raised high expectations of
short- and mid-term contributions to clinical innovation, which were
however followed by a cycle of disappointment (for primary literature
see: Anonymous, 2011; Lander, 2011; for secondary analysis see: Martin
et al., 2009; Hogarth et al., 2012). Advocates have positioned TR as the
approach that would make genomics and related technological platforms
relevant to the clinic (Collins, 2011). This involves, most notably,
modernising clinical research networks so as to make genetic sequencing
an integral part of clinical testing and the development of new interven-
tions, or expanding experimental platforms such as biobanks, which can
generate therapeutic hypotheses by directly using human tissues instead
of model systems.
The latest, but possibly the most urgent, series of developments to have
shaped the trajectory of TR concepts has been the increased perception of
a situation crisis in the pharmaceutical industry. With its 2004 report
Innovation/Stagnation, the US Food and Drug Administration brought the
existence of data indicating stagnating productivity in the pharmaceutical
industry in terms of new innovative drugs, despite increasing investments,
to the attention of a broad audience (Food and Drug Administration,
2004). Although the data and interpretations have been subjected to
discussion, by the late 2000s, events seemed to confirm the diagnosis.
Large pharmaceutical companies have recently slashed thousands of RTD
jobs as their recently off-patent portfolio ‘blockbuster’ drugs, selling for
billions annually, had failed to be replaced by new ones (Milne, 2009). In
prevision or in reaction to this situation, a number of biomedical leaders
and academic administrations had advocated the establishment of ‘aca-
demic drug pipelines’, hence providing for unprecedented forms of
development research, divisions of labour and industrial RTD equipment
within the public research systems (Tralau-Stewart et al., 2009; Becker
and van Dongen, 2011).
TR as policy rationale thus emerged as a response to these three
interconnected series of developments. Although the TR rationale repeats
many themes and proposals commonly voiced by reformers of bio-
medical innovation since the 1970s (Vignola-Gagné, 2014), the pro-
gramme has received unprecedented levels of commitment. It is now
backed by major research funds, training programs and institutes
(Zerhouni, 2005; Collins, 2011; Shahzad et al., 2011; von Roth et al.,
2011).
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7.4.2 Case Study Results
Section 7.4.2 presents the results of our case studies of TR initiatives. For
each case, the relevant policy instruments are described. It is then shown
how these instruments were introduced and put into operation by local
entrepreneurs, simultaneously, as they advocated for the adoption of the
TR model.
Based on interviews and literature studies described above, Table 7.1
below uses the four dimensions of socio-technical change advocated by
TR programmes (see section 7.1) to summarize the technological and
organizational changes that have taken place at the sites of each of our
three case studies.
Table 7.1 Forms and depth of socio-technical change brought by TR
initiatives in three regional biomedical innovation systems
ASC OncoTyrol TRAIN
Lab – clinic integration + + + +
Investment in gap areas + + + + + +
New division of labour – + + +
Enhanced coordination – + + +
7.4.2.1 Description of cases
The three cases studies from the Anna Spiegel Centre, OncoTyrol and the
Translational Research Alliance in Lower-Saxony are described below.
7.4.2.1.1 Anna Spiegel Center for Translational Research The Anna
Spiegel Center (ASC) is a research building situated at the Medical
University of Vienna (MUV), as part of the General Hospital of Vienna
(AKH). It has specifically been labelled as a translational centre and was
built with the intention to create more lab-space and to centralize ‘Core
Facilities’ – high-tech to support basic research at the AKH/MUV.
Opened in 2010, the centre is an example of a highly modern research
institute composed of relatively independent teams that were previously
situated in a more clinical environment at the main buildings of the
MUV.
The ASC consists of six research departments (surgery, dermatology,
cardiology, paediatrics, oncology and haematology), which comprise a
varying number of research and/or lab-groups. The official mission of the
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centre is to conduct clinically-driven research using the latest techniques
biomedical research has to offer. The chemists and biologists at the ASC
work closely together with the physicians at the clinic located at the main
building of the AKH/MUV. Their research projects are based on clinical
considerations/observations, and they try to translate their new findings
(new diagnostics, bio-markers) immediately to the clinic. Accordingly,
the scientific practices are translational in a bi-directional manner since
both areas – the lab and the clinic – need each other’s expertise and
knowledge. Moreover, this close relationship is based on ‘material
exchange’, as the basic researchers need, for example, tissue samples
from patients or bio-banks.
The ASC does not have a director or management team of its own. The
ASC staff have a very heterodox understanding of TR notions, ranging
from an economic conception to a more clinically oriented definition.
7.4.2.1.2 OncoTyrol OncoTyrol comprises a regional cluster of 22
research groups located in universities, research institutes and companies,
specialising in applied research in the growing field of personalized
cancer medicine in the area of Innsbruck. OncoTyrol operates as a GmbH
(limited liability company). The consortium is led by the board of
shareholders (56 per cent universities; 21 per cent Hospital Holding;
23 per cent Province of the Tyrol), and decisions are implemented by the
management in Innsbruck. Currently, OncoTyrol is employing about 90
scientists and providing facilities for the research teams (for example,
offices for HTA-research, lab-space in a special building, facilities for
bio-informatics).
The research teams are expected to produce patents, licences or
products in cooperation with industrial partners. Part of the IPR from the
funded projects is retained by the OncoTyrol management – a situation
which prompts the consortium administrators’ hope that it will become
self–sufficient in the future, without a need for additional public funding.
In terms of the sheer amount of industrial partners involved, OncoTyrol is
an atypical TR initiative. Although some industrial members act more as
mécènes, providing funding in the background in the hope of the
development of eventual products, other projects have called for joint and
sustained collaborations.
As a consortium with its own dedicated project funding mechanism,
OncoTyrol features a unique structure within the networks and initiatives
we have studied. Whereas in TRAIN, funding is mostly provided for
building and equipment infrastructure, in OncoTyrol, funding is given to
projects directly (including personnel costs). The OncoTyrol administra-
tion can decide (and has been known) to withdraw membership and
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funding from project teams that are not committed enough towards
clinical and/or commercial aims.
7.4.2.1.3 Translational Research Alliance in Lower Saxony The Trans-
lational Research Alliance in Lower–Saxony (TRAIN), a state in the
Centre–North of Germany, is an initiative explicitly dedicated to devel-
oping new drug compounds that are typically brought forward by
pharmaceutical corporations. TRAIN regroups seven main institutional
partners, all of which directly take part in various tasks and work
packages of the collaboration’s projects. The institutes are located in
relative proximity in the two largest cities of the region. Their founding
members include universities, public research institutes and a medical
school. A number of joint ventures between partner institutes have
significantly extended the local expertise in drug development. Further,
the consortium includes a firm specialized in managing life science
projects (VPM).
Based on the capacities that are being regrouped, the TRAIN manage-
ment claims that within the TRAIN partnership it is possible to go from
pathophysiological hypothesis to lead compound to early phase II clinical
trials (that is, clinical development with tests on human subjects to
measure safety and administration modalities, thus requiring a compara-
tively complex infrastructure). This claim positions the consortium as a
structure of unique breadth and complexity in Germany and at the
European level.
7.4.2.2 Pillar 2: policy instruments
As discussed in Section 7.1, a number of different policy instruments
have been advocated in the literature to realize the TR programme
(Vignola-Gagné and Biegelbauer, 2013; Vignola-Gagné et al., 2013).
Reformulated in the language of STI policy analysis, these instruments
most importantly include:
+ measures of organization building in the sense of creating the
infrastructure for TR;
+ funding programmes fostering TR, but also general research fund-
ing programmes;
+ the professionalization of education such as support for clinician-
scientists with degrees in both medicine and natural sciences;
+ efforts of governance coordination in which either various govern-
ance initiatives are coordinated and/or in which actors are brought
together in order to exchange information.
144 The governance of socio-technical systems
Columns Design XML Ltd / Job: Borras-Governance_of_SocioTechnical_Systems / Division: 07-Ch-7authorchecked /Pg. Position: 13
/ Date: 1/8
JOBNAME: Borras PAGE: 14 SESS: 3 OUTPUT: Mon Aug 4 11:05:11 2014
In all three case studies, measures of organization building and general
funding programmes proved to be most central. In the case of the ASC,
the funds that had been earmarked for the completion of the General
Hospital (AKH) were used for a building for two research institutions,
the Anna-Spiegel-Centre (ASC) and the Research Center for Molecular
Medicine (CeMM). The cost of 41 million Euro for the building was
shared between the city of Vienna and the Austrian Ministry for Science
and Research. Research at the ASC is supported by standard principal
investigator grants or project funding from thematic programmes (from
the Austrian Science Fund (FWF)’s general competitions, ‘Translational
Research’ and ‘Clinical Research’ (both FWF), ‘Patients in Focus’
(Centre for Innovation and Technology of Vienna, ZIT) and the life
science programmes of the Vienna Science and Technology Fund
(WWTF)).
OncoTyrol was mostly funded by the Austrian COMET programme
(Competence Centres for Excellent Technologies; Biegelbauer, 2007), a
multi-actor, multi-purpose competence centre programme, aiming at
linking actors in science and industry by realising cooperative research
initiatives co-funded by federal and state (Länder) levels, companies and
research institutions. When its predecessor Kplus was set up in 1998, it
was arguably the most complex RTI policy instrument in Austria and in
2013 it remains to be one of the most important RTI funding instruments
in the country (Biegelbauer, 2013b). In addition to COMET funding
(from 2008–2012, approximately 18 million Euro came from the federal
level, 6 million from the state of Tyrol, 23 million from industry and
1 million from academia), additional support stems from a variety of
research funding programmes. Broadly, the OncoTyrol consortium can be
said to have been assembled by the combination of policy instruments
commonly used in the last 20 years to foster commercially-oriented STI
activities: centres of excellence with a high level of participation from
industrial partners; the availability of venture or seed capital; and high
interdisciplinarity. Nonetheless, the specific configuration of expertise
and disciplines present within the consortium, especially its emphasis on
fostering clinically-informed laboratory research, is aligned with TR
rationales.
TRAIN institutionalizes previously dispersed regional expertise in drug
development in a clear model, through regional coordination and
cooperation, and a consensual division of labour between local actors.
This policy plan was jointly developed by local leaders of relevant
institutions and the Lower Saxony Ministry of Science and Culture. The
model makes direct reference to the rationale of academic pipelines (see
section 7.4.1), thus providing ‘blueprints’ for local TR projects, including
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model collaborations. The central office of the initiative (staffed by one
part-time administrator), together with the life sciences project manage-
ment firm VPM, encouraged active participation of research teams that
are affiliated with consortium member institutions. The business man-
agers and coordinators were central agents for transforming research
projects of autonomous teams into complex TR projects with centralized
coordination and strategic commercial planning. The consortium model
also assigned specific tasks to different expert groups within the consor-
tium. The infrastructure building activities that have taken place there
since 2007, especially multiple joint ventures, have helped to establish
the consortium collaboration blueprint more readily. A first wave of such
joint ventures was initially funded by the local Lower Saxony Ministry of
Science and Culture (at the level of slightly under 30 million Euro). With
this initial funding secured and the overarching concept established,
members of the consortium have also been able to secure infrastructure
funding for other joint institutions from the German federal programme
for university infrastructure building, the Forschungsbau programme.
Despite the focus on infrastructure funding up to now, business
managers and coordinators at the consortium central office can also assist
member teams with obtaining grants or venture capital to finance actual
experimental work. A drug development project related to the consortium
benefitted, for example, from funding from the German federal Bio-
Profile programme, which offers proof-of-concept funding for explora-
tory development work in the life sciences conducted in biotechnology
firms or academic settings. Drawing on this funding, and directed by
principle of the ‘academic pipeline’, the TRAIN consortium has thus
focused on the development of the large-scale equipment used in
industrial drug development, including natural substance libraries and a
chemical screening facility.
OncoTyrol is an interesting case here as the COMET funding
programme allows funding of research groups and facilities alike and
thus offers OncoTyrol’s management some flexibility. Yet COMET
funding is tied to a number of conditions, most importantly science-
industry cooperation. In order to provide the management with the
structures necessary for coordinating competence centres with a large
number of actors with diverse multi-disciplinary commercial and non-
commercial background, COMET centres are set up with a clear
hierarchical structure (Biegelbauer, 2007). OncoTyrol features a network
structure combined with a strong hierarchical component, while ASC
and TRAIN are less hierarchical. Leadership in ASC is externalized in
the form of the management of the AKH/MUV. TRAIN’s strongest
management structure is the cluster formed by a steering committee in
146 The governance of socio-technical systems
Columns Design XML Ltd / Job: Borras-Governance_of_SocioTechnical_Systems / Division: 07-Ch-7authorchecked /Pg. Position: 15
/ Date: 1/8
JOBNAME: Borras PAGE: 16 SESS: 3 OUTPUT: Mon Aug 4 11:05:11 2014
which representatives of the six founding partner institutions are
co-located with the consortium administration office.
7.4.2.3 Pillar 1: opportunity structures and capable agents
The cases of TR collaborations we studied have highlighted the central
role of a few academic leaders in implementing local iterations of the
proposals made in the international policy discussion. They show how the
emerging policy rationale, and its specific repertoire of problems and
solutions, was used by these entrepreneurs to reframe collective interpret-
ations of the biomedical innovation process shared by local actors, and of
their preferred policy instruments.
Within TRAIN, understandings of TR have been most thoroughly
shaped by the sub-rationale of crisis in innovation productivity in the
pharmaceutical industry. The consortium leaders are also very clear about
the origins of this initiative as a response to the pharmaceutical innov-
ation crisis. The uptake of the consortium model has been actively
advocated among the member institutions by information sessions or
‘internal PR’. In their presentations, consortium coordinators directly
refer to the models recently expounded by Francis Collins, the current
director of the US National Institutes of Health (NIH), who has called for
universities and public institutions to take on some of the scientific risk
associated with drug development and increase collaboration with the
pharmaceutical industry. The explicit goal of these information activities
is to promote the TR model of biomedical innovation locally among
research teams and other relevant actors, some of them being core
funders at the regional and federal level. Establishing the TRAIN
consortium has thus called for action on local work programmes,
problematizing capacities for biomedical innovation and presenting the
TR model as the preferred solution. Nonetheless, consortium leaders also
worked at the level of resources and incentives, offering expertise to
potential partners with regard to business management, patent portfolio
development or networking with venture capital. The TRAIN entre-
preneurs aligned governmental funding schemes and other policy instru-
ments with the demands of local projects to realize a coherent TR
network that is in accordance with current rationales about biomedical
innovation.
OncoTyrol’s origins lie in the strong departments for clinical oncology
at the Medical University Innsbruck and related biological research
centres. In 2002, this collective of excellent scientists already present in
Innsbruck was consolidated into a better network by a prime mover with
a background both in science and industry. Notably problematic at that
point was a perceived financing gap for proof-of-concept studies, which
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meant that promising therapeutic intervention candidates, who had been
developed locally, were ‘lost’ to industry instead of being led through
early clinical development within Medical School.
The opportunity to establish an excellence centre for oncology arose
when COMET calls for application were issued. Similar to TRAIN, the
founders of OncoTyrol seized the increasing difficulties within the
pharmaceutical industry as an opportunity to elaborate a centre of
excellence model centred around ‘open innovation’ (they made an
explicit reference to the work of Henry Chesbrough), with strong
networks of collaboration between the Medical University and industry
partners. This way, tentative TR projects would obtain proof-of-concept
funding and access to industry-specific competences and infrastructures
while retaining more control over product development than was previ-
ously possible.
With the excellence centre approved and in place, the coordination of
participating TR projects changed dramatically. The consortium directly
employs more than 80 administrative and technical staff, and participat-
ing research teams obtain most of their project funding and even salaries
through the OncoTyrol administration. Continued availability of this
funding is subject to successful progress in TR terms, and in terms of
clinical and commercial relevance. COMET funding, which itself was
marshalled by a few entrepreneurs that identified a unique support
opportunity and made use of the international rationale of TR to advocate
their vision, thus durably altered the structures of opportunity for regional
biomedical actors as well as their understanding of TR. While the
compliance of participating research teams with the TR model does not
rest on its advocacy by the entrepreneurs alone (as it does in TRAIN), the
OncoTyrol leadership nonetheless has made use of its programmatic
statements in preparing future expansions of the consortium (including a
move towards financial self-sufficiency).
In the case of ASC, several scientific entrepreneurs came to the
conclusion that lab space was too limited in the Medical University
Vienna and therefore infrastructure building was the only possible
solution to the problem. In lengthy negotiations with the City of Vienna
and the Austrian Ministry for Science it became clear that a new building
would become more feasible when sharing space with a second institu-
tion. This turned out to be CEMM, which was at this time rapidly
expanding and therefore also looking for a new building.
Labelling the building with TR coincided with the fact that different
elements of the TR metaphor had already taken root in Austrian RTI
policy discussions, leading to the first TR funding programmes at the
time. Policymakers therefore were receptive to the programme of TR,
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with its affinities for their own commitment towards the renewal of
medical schools. However, once they had successfully marshalled funds
for their infrastructure and equipment project, the entrepreneurs however
did not push through with the organizational interventions advocated in
international TR programmes.
7.4.2.4 Pillar 3: questions of legitimacy
To a certain extent, we can reduce the question of opportunity structures
surrounding TR to the issue of legitimacy in biomedical innovation
systems. The opportunity for TR consortium building appears to have
been thoroughly shaped by global policy discussions about how best to
conduct biomedical innovation so as to ensure its continued relevance in
the eyes of a broad civil constituency, as well as its ‘value for money’ (in
the sense of Braun, 2005; see also Leonelli and Sunder Rajan, 2013;
Maeinschein et al., 2008).
Despite this potential for making TR a vehicle for extended civil
participation in RTD systems, our results show that this has not been the
case in Austria and Germany. The consortia we studied had no mechan-
ism to ensure patient or citizen input into decision-making. Interview
respondents sometimes considered the market’s demand for given health
products, or that clinicians’ experiences with patients provided the best
means to capture patient or end user preferences, with even patient
representatives being sceptical about the possibility of co-decision mak-
ing regarding TR on grounds of the involved issues’ complexity.
This does not mean that legitimacy is not an important dimension in
order to make sense of the changes brought about by TR in biomedical
innovation systems. Indeed, ‘internal’ or intra-network legitimacy, as a
resource that can be deployed to ensure coordination and collaboration
within the narrowly defined communities of innovation studied here was
a central concern of the consortia. This can be most clearly witnessed in
the case of TRAIN, where, as discussed above, the actual realization and
performance of the consortium model depended on well-coordinated
collaboration of a number of research teams with broadly different
disciplinary and organizational missions and demands to answer to.
Establishing participation in TRAIN as a new and distinct goal for each
of these teams thus entails building legitimacy for the project that
answers to the necessarily particularistic (with respect to the consortium’s
goals) agendas of these groups of experts.
While within OncoTyrol, the broader discussion of crisis in biomedical
innovation played some role in its overall set-up and direction of the
consortium, it was less prominent and somewhat less operationalized in
the case of TRAIN. Indeed, because of direct management of research
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funding by the central administration, it seemed that the official narrative
was not being extensively used in daily practice. Nevertheless, legitimate
participation of research teams within the OncoTyrol structure depended
on their compliance with collaboration and experimental practices in line
with those advocated in TR rationales.
In the case of the ASC, TR had little effect on intra-network legitim-
acy. Since the legitimacy of the organization rests on a strong scientific
rationale, it is well aligned with the mind-set of scientists and medical
doctors working there. The internal governance schemes of ASC are very
much driven by the experienced principal investigators leading small
research groups, who coordinate loosely and without much internal
differentiation. The framework of the organization is predefined by the
MUV’s rectorate, which conceives of the ASC as an institution for
scientific excellence, where only the best research groups of the MUV
should work. Accordingly, these groups were chosen by MUV in a
selection procedure based on scientific output criteria only. ‘Intra-
network legitimacy’ is of course interconnected with ‘extra-network
legitimacy’. The TRAIN leaders advocate to local partners the model
proposed with their consortium by framing the current biomedical
innovation policy landscape as threatened by a crisis with far-reaching
consequences. Consortium leaders thus readily draw on debates around
the legitimacy of the biomedical innovation enterprise and its relevance
to civil society to justify their agendas.
Interestingly, consortium collaborators sometimes appeared to be
‘phantom allies’, that is partners more on paper than in practice, yet
useful in order to keep current core collaborations going with the
prospect of future collaborations around commercial development, for
example. These phantom allies (most notably industry and patients)
imbued the work blueprint provided by the consortium with legitimacy,
and thus provided consortium leaders with resources to align academic
members and ensure effective coordination of their work within the
division of labour planned by the model. In other words, the ‘presence’ of
these phantom allies had essentially boosted the legitimacy to alter local
interpretative frameworks related to the biomedical innovation process
and to marshal support from a number of policy instruments.
The ASC, for its part, consolidated an orientation towards laboratory-
based research on human material that was already present at the MUV.
As such, it provides a case of TR as a transformative notion being used in
a non-transformative manner and to extend previously existing practices.
Nevertheless the external legitimacy of ASC secured funding for infra-
structure which was justified by a broader importance beyond ASC. This
utilization of TR as a legitimising metaphor includes the instrumental
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usage of firms, which are again being used as ‘phantom allies’ and which
in the actual daily practices of the organization until now have played a
rather small role – something which may or may not change with an
increasing age of the still young institution. Firms, however, were not the
only ‘phantom allies’ – patients also tended to slip out of the roles
assigned by programmatic statements. In the actual daily routines of ASC
personnel, patient participation in the research process was mostly
limited to tissue donation.
7.5 DISCUSSION
The material and analysis presented above provided multiple points of
support for our argument that traditional STI policy analysis can benefit
from closer attention to programmatic statements and their deployment in
advocacy practices by change–bearing entrepreneurs.
To demonstrate this, we have drawn support from empirical cases
showing how a set of socio–technical changes – that is, the closer
integration of clinical experience with laboratory experimentation, invest-
ment in gap areas, new professional roles and greater coordination of
projects – in some biomedical innovation systems has been recently
affected by the emergence of a new policy rationale called TR. At the
international level, this emergence has notably been fostered by parallel
interventions and advocacy from academic leaders, academic administra-
tions and STI policy–makers. Yet, this new policy rationale does not map
out directly into a specific set of policy instruments that could be used to
deploy or implement its proposals, at least not in Germany and Austria,
where the networks we studied are located. We are not presented with a
‘linear model of policy formulation and implementation’, where one
issue would be linked with one set of policy instruments, which in turn
would translate to one defined set of behavioural and organizational
impacts in innovation systems.
Instead, multiple issues and policy instruments co-exist in various
relations, and ‘impact’ in innovation systems may well be achieved by
new alignments of actors to long-existing instruments. Indeed, in our case
studies, local entrepreneurs made opportunistic use of various pre-
existing instruments. These instruments were useful for building an
innovation network modelled after TR programmes, helping to enrol
local allies to take on parts of the necessary labour. As such, local
implementations and deployment of existing policy instruments were
inflected and performed through governance processes such as the
reframing of legitimate experimental practices affected by advocacy of
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TR notions. New policy instruments put into place for the networks
(mostly infrastructure funding) were sometimes also a consequence of
previous advocacy. Furthermore, advocacy work was greatly aided by
previous network building efforts. That is, building a successful collabor-
ation to engage in multidisciplinary TR projects itself functioned as a
powerful argument to enrol further allies.
Sometimes, this also meant that advocacy was constantly required to
hold the emerging system together. Even in the case of the TRAIN
consortium, which can be characterized as one whole and well planned
policy instrument, implementation and collaboration of local actors has to
be constantly maintained. Different local actors had different interpret-
ations of the challenges facing biomedical innovation and might not join
the TRAIN way of doing things.
Here, changes in programmatic orientation and deployment of classical
STI policy instruments seamlessly rubbed shoulders with one another and
even fed on each other. Local entrepreneurs drove these changes,
supporting their contentions and actions on higher-order policy narratives
made culturally available in biomedical policy networks.
In the OncoTyrol case, instead, the availability of locally yet centrally
managed research money made use of programmatic TR statements with
a coordinative intent less salient. That is, here the potency of a classical
STI policy instrument (a centre of excellence) enabled the consortium
management to ensure better, more direct coordination of the research
teams. The formal programme of TR gave legitimacy and justification to
an organizational model that was quite different from what participating
researchers had been accustomed to in a purely academic context.
TR was used in an even more metaphoric way with ASC, where it was
used as a recognizable symbol to link the idea of creating a new centre of
excellence for biomedical research to pre-existing discussions on defi-
ciencies in the cooperation between basic science and clinical application
of research findings. Moreover, central management functions remained
with the AKH/MUV, which is another factor that worked against the
emergence of strong entrepreneurial and advocacy activities around the
TR programme in the ASC case.
In TRAIN and OncoTyrol TR was systematically interpreted in a
strong alignment towards industry collaboration. Yet, efforts by the
consortium leadership to realize this seem to have fallen a bit short of the
rhetoric of ‘close integration’. Instead, industry partners in TRAIN,
OncoTyrol, but also the ASC, often appeared as ‘phantom allies’ whose
participation was an important signifier of success, but who ultimately
made modest contributions to actual experimental activities. Similarly,
patient orientation is generally considered a modus operandi of TR, also
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repeated in presentations of TRAIN, OncoTyrol and ASC, yet actual
involvement was nowhere to be found.
Jacobsson and Lauber (2006) highlighted the role that advocacy
coalitions can play in STI policy, especially in building legitimacy for
given projects or programmes and aligning institutions around the
corresponding goals. In other words, much like us, they find that
legitimacy is a central component of innovation systems and the policies
that target them. Nonetheless, these authors concentrated on high-order
changes in rationale and corresponding legislative pressure as a main
driver of STI policy change. What we have seen here is that legitimacy
building through the formulation and advocacy of programmes is also an
essential factor in the implementation of policy instruments. Deliber-
ations about common goals, programmes or rationales can take place at
the ‘grassroots’ level of innovation systems, especially through the work
of entrepreneurs, as much as it does in parliaments and the offices of civil
servants. Additionally, in the cases examined here, existing policy instru-
ments were re-aligned and given new impacts through their use within
new networks dedicated to TR. We should therefore not posit that new
programmes and rationales act on the governance of STI activities only
in the formulation phase of policy instruments, but that they are central
determinants of policy transfer and implementation as well.
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Interviews
TRAIN case study
TRAIN Interview #1A: Staff, Twincore, Hannover; Interview in Hannover on
29 October 2010.
TRAIN Interview #1B: Staff, Twincore, Hannover; Interview in Hannover on
10 January 2012.
TRAIN Interview #2: Staff, VPM GmbH, Hannover; Interview in Hannover on
13 December 2011.
TRAIN Interview #3: Professor, Eberhard Karls University Clinic Tübingen;
Interview in Tübingen on 19 December 2011.
TRAIN Interview #4: Staff, Twincore, Hannover; Interview in Hannover on
10 January 2012.
TRAIN Interview #5: Scientific Coordinator, Helmholtz Center for Infection
Research, Braunschweig; Telephone interview on 18 January 2012.
TRAIN Interview #6: Staff, Niedersächsisches Ministerium für Wissenschaft und
Kultur Hannover; Telephone interview on 9 March 2012.
Anna–Spiegel–Center Case study
ASC Interview #1: Head of a research group, Professor; only located at the ASC;
Interview in Vienna on 9 December 2011.
ASC Interview #2: Head of a research group; trained as biologist; Ao. Professor;
only located at the ASC; Interview in Vienna on 19 December 2011.
ASC Interview #3: PhD–student; trained in molecular biology with specialization
on genetics and biomedicine; in her second year; located in the research group
of #1; mainly located at the ASC; Interview in Vienna on 19 December 2011.
ASC Interview #4: Head of a research group, trained as biologist, Ao. Professor;
only located at the ASC; Interview in Vienna on 4 January 2012.
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ASC Interview #5: Assistant head of a clinical department, Professor; responsible
for a small lab team, but mainly located at the clinic; Interview in Vienna on
16 January 2012.
ASC Interview #6: Research direction at the MUV, head of department and
Professor; located at the main building of the MUV/AKH; Interview in Vienna
on 17 January 2012.
ASC Interview #7: Head of a research group, trained as chemist (PhD); Interview
in Vienna on 20 January 2012.
ASC Interview #8: Direction, laboratory of the university clinic, located at main
building; Interview in Vienna on 2 April 2012.
ASC Interview #9: Joint Interview with one chemist, responsible for a core
facility, and one principal investigator; Interview in Vienna on 16 December
2012.
ASC Interview #10: Interview with administrative staff of the MUV; Interview in
Vienna on 8 May 2012.
ASC Interview #11: Administrative staff, university clinic; Written answer to the
interview questionnaire provided on 18 May 2012.
OncoTyrol case study
OncoTyrol Interview #1: Joint Interview with two principal investigators, Medi-
cal University of Innsbruck; Interview conducted in Innsbruck on 13 February
2012.
OncoTyrol Interview #2: Industry partner, Innsbruck; Telephone interview con-
ducted on 23 March 2012
OncoTyrol Interview #3: Joint interview with two administration staff, Onco-
Tyrol Management; Interview conducted in Innsbruck on 21 February 2012.
OncoTyrol Interview #4: Research direction staff, OncoTyrol Office and Profes-
sor, Medical University of Innsbruck: Interview conducted in Innsbruck on 22
February 2012.
OncoTyrol Interview #5: Industry Partner, Vienna; Interview conducted in Vienna
in 19 March 2012.
OncoTyrol Interview #6: Industry Partner, Zürich; Telephone interview con-
ducted on 21 March 2012.
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